Heart Failure, Mirabegron, Pulmonary Hypertension, Pulmonary Vascular Resistance Abnormality
Conditions
Keywords
Pulmonary hypertension, Mirabegron, Heart failure, B3 adrenergic
Brief summary
The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3 adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart failure by conducting a randomized multicenter phase II placebo-controlled clinical trial.
Detailed description
Pulmonary hypertension (PH) affects 60-80% of patients with chronic heart failure (HF) and has a critical impact on prognosis. Currently, there is no specific treatment approved for this indication. Experimental research, performed by members of the consortium, demonstrates that treatment with B3 adrenergic receptor agonists produces a beneficial effect on pulmonary hemodynamics, right ventricular (RV) remodeling and pulmonary vascular proliferation in a translational pig model of postcapillary PH. Mirabegron, an oral B3AR agonist, is currently approved for a different medical condition (overactive bladder syndrome) with a good safety profile. Our main objective is to evaluate the efficacy and safety of mirabegron in patients with PH secondary to HF. The objective will be evaluated by conducting a phase-2 randomized placebo-controlled clinical trial in patients with PH associated to HF. Patients will be randomized 1:1 to mirabegron or placebo, and dose will be titrated till 200 mg/day. Patients will be evaluated with quality of life questionnaire, blood analysis, ECG, echocardiography, 6-minute walking test, right heart catheterization (RHC) and cardiac magnetic resonance (CMR) at baseline and after 16 weeks of treatment.
Interventions
DRUGMirabegron
Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
DRUGPlacebo
Sponsors
Hospital Clinic of Barcelona
Hospital Universitario 12 de Octubre
Puerta de Hierro University Hospital
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written inform consent; * \>18 years-old; * HF with reduced or preserved ejection fraction, according to the definition of the European Society of Cardiology guidelines. * Severe PH and/or combined postcapillary and precapillary PH (also knows as reactive or out-of-proportion PH) determined by RHC showing the following: * Pulmonary arterial wedge pressure or end-diastolic left ventricular pressures ≥15 mmHg; * Mean PAP≥25, and: * PVR≥3 UW and/or diastolic gradient≥7 mmHg or * Transpulmonary gradient≥12. * NYHA functional class II-IV; * On optimized evidence-based pharmacological treatment; * Stable clinical condition defined as no changes in therapeutic regimen or hospitalization in the 30 days preceding recruitment and no current plan for changing therapy.
Exclusion criteria
* Non-coronary cardiac surgery or non-coronary percutaneous procedure within the 12 months preceding recruitment or programmed; * Myocardial infarction or coronary revascularization during the last 3 months, * Myocardial resynchronization therapy initiated during the last 6 months; * Sinus tachycardia or atrial fibrillation with uncontrolled heart rate (\>100 bpm); * Uncontrolled hypertension (PAS\>180 or PAD\>110 mmHg) or symptomatic hypotension (PAS\<90 mmHg). * Infiltrative myocardial disease. * Expected survival \<1 year due to a disease other than PH; * Severe renal failure (GFR \<30 mL/min/1.73 m2 or haemodialysis); * Severe hepatic impairment (serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>3x the upper limit of normality at screening; * cQT interval on the ECG \>430 ms in male or \>450 ms in female; * Concomitant use of specific pulmonary vasodilator therapy (i.e. endothelin receptor antagonists, phosphodiesterase -5 inhibitors, guanylate cyclase stimulators). * Concomitant use of digoxin, flecainide, propafenone, dabigatran, tricycle antidepressants, or another strong inhibitors of CYP2D6 (with the exception of betablockers). * Significant obstructive lung disease (FEV1/FVC\<0.7 associated with FEV1\<50% of predicted value). * Significant restrictive lung disease (TLC\<60%). * Participation in another clinical trial. * Female with childbearing potential. * Known hypersensitivity to mirabegron or to any of its excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in pulmonary vascular resistance (PVR) from baseline to week 16 assessed by right heart catheterization (RHC). | 16 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in NYHA functional class | 16 weeks |
| Change from baseline in quality of life | 16 weeks |
| Change from baseline in dyspnea Borg score | 16 weeks |
| Change from baseline in mean PAP as assessed by RHC | 16 weeks |
| Change from baseline in cardiac index (CI) as assessed by RHC and cardiac magnetic resonance (CMR) | 16 weeks |
| Change from baseline in RV ejection fraction as assessed by CMR | 16 weeks |
| Change from baseline in 6-minute walking distance | 16 weeks |
| Hospital admissions due to worsening cardiopulmonary status | 16 weeks |
| Mortality | 16 weeks |
| Urgent heart transplantation | 16 weeks |
| New onset arrhythmia | 16 weeks |
| Need for initiation of intravenous therapy due to worsening HF | 16 weeks |
| Adverse drug effects | 16 weeks |
| Change from baseline in BNP/NT-proBNP | 16 weeks |
Contacts
Primary ContactAna García-Álvarez, MD, PhD
Backup ContactBorja Ibañez, MD, PhD
Outcome results
None listed